CSL (OTCMKTS:CSLLY) Shares Gap Down - Should You Sell?

Key Points

• CSL Limited's stock gapped down significantly, opening at $66.55 after closing at $68.67, and is currently trading down 1.0%.
• Zacks Research has upgraded CSL's rating from "hold" to a "strong sell", while MarketBeat lists an average rating of "Moderate Buy".
• The company's current financial metrics indicate a healthy position, with a current ratio of 2.46 and a debt-to-equity ratio of 0.50.

CSL Limited Sponsored ADR (OTCMKTS:CSLLY - Get Free Report) gapped down before the market opened on Monday . The stock had previously closed at $68.67, but opened at $66.55. CSL shares last traded at $68.02, with a volume of 14,466 shares traded.

Analyst Upgrades and Downgrades

Separately, Zacks Research downgraded shares of CSL from a "hold" rating to a "strong sell" rating in a report on Monday, September 15th. One equities research analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy".

CSL Trading Down 1.0%

The firm's 50 day moving average is $74.11 and its two-hundred day moving average is $77.35. The company has a current ratio of 2.46, a quick ratio of 1.12 and a debt-to-equity ratio of 0.50.

CSL Company Profile

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.